(R)-SR-C-107 is a potent, orally bioavailable small molecule inhibitor targeting the ENL YEATS domain for acute myeloid leukemia (AML) research. It exhibits an IC50 of 40 nM and a KD of 144 nM against ENL. In an AML xenograft model, oral administration (200 mg/kg, QD) induced 45% tumor regression, demonstrating significant in vivo efficacy.
Molecular Weight:
389.45
Formula:
C21H23N7O
Target:
Epigenetic Reader Domain
* VAT and and shipping costs not included. Errors and price changes excepted
